ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,779 | $3 | $5 | $2 |
| G&A Expenses | $7,358 | $11,213 | $8 | $6 |
| SG&A Expenses | $7,358 | $11 | $8 | $6 |
| Sales & Mktg Exp. | $0 | -$11,202 | $0 | $0 |
| Other Operating Expenses | -$9,128 | $0 | $1 | $0 |
| Operating Expenses | $9 | $14 | $14 | $8 |
| Operating Income | -$9,137 | -$14 | -$14 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$283 | -$93 | -$1 | -$0 |
| Pre-Tax Income | -$9,420 | -$108 | -$15 | -$8 |
| Tax Expense | -$7 | -$9 | -$1 | $0 |
| Net Income | -$9,413 | -$98 | -$14 | -$8 |
| % Margin | – | – | – | – |
| EPS | -8.48 | -1,089.66 | -930.25 | -173.66 |
| % Growth | 99.2% | -17.1% | -435.7% | – |
| EPS Diluted | -8.48 | -1,089.66 | -930.25 | -173.66 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9,137 | -$108 | -$14 | -$7 |
| % Margin | – | – | – | – |